Recent advances in the development of alternative proangiogenic and revascularization processes, including recombinant protein delivery, gene therapy, and cell therapy, hold the promise of greater efficacy in the management of cardiovascular disease in the coming years. In particular, vascular progenitor cell-based strategies have emerged as an efficient treatment approach to promote vessel formation and repair and to improve tissue perfusion. During the past decade, considerable progress has been achieved in understanding therapeutic properties of endothelial progenitor cells, while the therapeutic potential of vascular smooth muscle progenitor cells (SMPC) has only recently been explored; the number of the circulating SMPC being correlated with cardiovascular health. Several endogenous SMPC populations with varying phenotypes have been identified and characterized in the peripheral blood, bone marrow, and vascular wall. While the phenotypic entity of vascular SMPC is not fully defined and remains an evolving area of research, SMPC are increasingly recognized to play a special role in cardiovascular biology. In this review, we describe the current approaches used to define vascular SMPC. We further summarize the data on phenotype and functional properties of SMPC from various sources in adults. Finally, we discuss the role of SMPC in cardiovascular disease, including the contribution of SMPC to intimal proliferation, angiogenesis, and atherosclerotic plaque instability as well as the benefits resulting from the therapeutic use of SMPC.
Introduction
Cardiovascular disease, encompassing ischaemic heart disease, stroke, peripheral arterial disease, and other disorders affecting the vessels that supply many vital organs, remains the leading cause of morbidity and death worldwide. 1 Pharmacological and interventional revascularization procedures, currently used to treat these diseases, remain insufficiently effective. Associated with vascular dysfunction and impairment, cardiovascular disease may greatly benefit from the recently developed proangiogenic and provascularization strategies. Several novel provascularization therapies based on gene transfer and growth factor delivery have been evaluated in clinical trials. To date, most of them failed to demonstrate significant clinical and functional improvement. 2 In the last two decades, cell therapy-based approaches have emerged as a promising therapeutic option for cardiovascular disease. After the identification of endothelial progenitor cells (EPC) (for full list of abbreviations, see Table 1 ) in 1997 by Asahara et al., 3 it has become increasingly evident that vascular repair and remodelling is accomplished in part through the recruitment of vascular progenitor cells. 4 Thereafter, circulating vascular smooth muscle progenitor cells (SMPC) were isolated and characterized. 5, 6 Since then, numerous studies on phenotypic and functional properties of EPC and their use for therapeutic revascularization have been conducted, while the identity and function of SMPC have received less attention and have only recently become clarified.
In this review, we discuss recent data on the phenotypic features of SMPC, their role in pathological angiogenesis and intimal proliferation, and the therapeutic benefits resulting from the use of SMPC for the treatment of cardiovascular disease.
Defining vascular SMPC
Vascular SMPC can be defined as circulating or resident cells localized within the bone marrow (BM), vascular wall, or perivascular area, committed to the smooth muscle fate and capable of differentiating into mature smooth muscle cells (SMC), either in vitro, under appropriate culture conditions, or in vivo, at the site of active angiogenesis and vascular repair. Vascular SMPC are kept in an undifferentiated state within putative 'vasculogenic zones/niches' 7, 8 throughout the body.
The immaturity of SMPC is maintained due to the action of particular repressor/silencer mechanisms consisting of cues from the niche environment and several transcriptional repressor proteins and non-coding RNAs implicated in blocking the CArG-serum response factor (SRF)-myocardin axis essential for SMC differentiation (reviewed in Majesky et al. 9 and Xiao et al. 10 ). In addition, SMPC display a unique pattern of epigenetic control mechanisms, including a subset of covalent modifications of specific histone residues conditioning the activity or silencing of gene loci encoding SMC marker genes. 9 Counteracting these mechanisms during normal development or in disease allows SMPC to migrate from their niches, proliferate, and differentiate into mature SMC, which are highly specialized contractile cells whose function in vessels is the regulation of vascular tone, homeostasis, blood pressure, and blood flow distribution. 11 Vascular SMC are distinguished from visceral SMC by their distinct origin, localization within the body, type of contraction, and molecular mechanism guiding SMC specification. 12, 13 Visceral SMC and their progenitors (present, for example, in
the digestive system and the bladder) as well as tumour vasculature and proliferation are beyond the scope of this review. Cell surface differentiation antigens allowing for the identification of SMPC have not yet been identified, nor the specific intracellular markers allowing for their distinction from the mature SMC. At least three criteria are typically used to ascertain the identity of SMPC.
(i) Immunocytochemical and fluorescence-activated cell sorting analyses of putative SMPC expanded in vitro to detect the expression of several contractile and other specialized smooth muscle proteins, such as smooth muscle a-actin (aSMA), SM22a, smooth muscle myosin heavy chain (SM-MHC), calponin, caldesmon, smoothelin, and more recently, myocardin. 9, 14 Among these markers, SM-MHC seems to be the most specific to the SMC type. 11, 15 However, SM-MHC is expressed in terminally differentiated SMC and, for this reason, is not useful for the identification of putative SMPC. None of the remaining markers could be considered as strictly smooth muscle-specific because of their shared expression in several related cell types, including cardiomyocytes, myoepithelial cells, myofibroblasts/stellate cells, and activated fibroblasts, in particular within tumour stroma. 16 -18 (ii) The second criterion for the identification of SMPC is functional, which is the capacity of the cell to fulfil SMC-specific functions, including contraction upon stimulation with smooth muscle-specific pharmacological agonists, ability to support capillary-like structure formation in the in vitro assays, and vascular engraftment in the in vivo models. (iii) The third approach to define SMPC consists of the in vitro smooth muscle colony-forming assays, which determine the capacity of cells to give rise to clonal progeny developing a complete SMC phenotype in vitro. Smooth muscle outgrowth cells (SOC) were isolated from human peripheral blood 5, 19 and umbilical cord blood (UCB-SMPC) 6 and were shown to give rise to cells that express SMC-specific proteins, including aSMA, SM22a, SM-MHC, and calponin, 5, 6 but also the common haematopoietic progenitor cell (HPC) and EPC markers, such as CD34, foetal liver kinase 1 (Flk1)/vascular growth factor receptor-2, and CD133 ( Figure 1) . 5, 20 We demonstrated that UCB-SMPC were capable of contracting upon stimulation with carbachol, becoming incorporated into a capillary-like network formed by EPC in a threedimensional collagen culture, and homing to tumour vasculature in vivo, thus suggesting that they are the most probable candidate for bone fide SMPC. 6 SMPC appear to be divergent from EPC, although some studies report on the expression of surface markers shared with EPC by some SMPC preparations, 5 and even the possibility of transdifferentiation of EPC into SMPC. 21, 22 SMPC are neither multipotent nor pluripotent, have a limited ability to self-renew, and are, therefore, distinct from the more immature cell types, such as mesenchymal stem cells (MSC) 23 or adult pluripotent stem cells (APC), 24, 25 although the expression of stem cell markers in SMPC has not been addressed.
Origin and endogenous sources of SMPC
The developmental origin of SMPC is still not clearly determined. In contrast to EPC which, with some exceptions, commonly arise from a bipotent mesodermal ancestor, the haemangioblast, 26 more recently redefined as haemogenic endothelium, 27, 28 there is a great diversity in the embryonic sources of SMC from different vessels, and even from different segments within the same vessel (reviewed in Majesky 29 ). Lineage mapping and genetic-tracking studies demonstrated the existence of two major sources of SMPC in the embryo-neural crest 30, 31 and mesoderm-derived structures, including somites, 32, 33 epicardial mesenchyme, 34 and secondary heart field. 35 The adult SMPC pool was likely built from these various SMC-contributing embryonic cell populations seeded in the vicinity of vessels during embryonic development.
In the developing embryo, in addition to EPC and HPC, SMPC constitute a third major component of extraembryonic splanchnic mesoderm, where vasculogenesis occurs, and segregate early from the common haematopoietic/endothelial precursor, before the separation of haematopoietic and endothelial lineages. 36 According to the model proposed by Cossu and Blanco, 37 Flk1-positive primitive angioblasts give rise to two types of progenitors: bipotent T-cell acute lymphocytic leukaemia 1 (Tal1)-positive haemangioblasts and multipotent Tal1-negative mesoangioblasts, which are the multilineage mesenchymal progenitors that express Flk1 and physically associate with the embryonic dorsal aorta. Indeed, these authors isolated multipotent cells positive for the EPC markers CD34, Flk1, and Kit, capable of selfrenewal, of differentiation into various mesodermal cell types in vitro, and of engraftment to blood, cartilage, bone, and smooth, skeletal and cardiac muscle in vivo. 38 It has been suggested that these cells remained associated with the abluminal face of the endothelium throughout development and make up the adult pool of pericytes, 37 which is another putative source of SMPC. In adults, SMPC were identified in the circulation, in the neointima, media, and adventitia of the vascular wall, and in the perivascular space. The phenotypic and functional properties of these different SMPC populations are listed in Table 2 .
Circulating SMPC
The existence of circulating SMPC was originally inferred from animal studies that demonstrated the possible recruitment of circulating BM-derived cells to sites of arterial remodelling and the ability of haematopoietic stem cells to differentiate, in vitro and in vivo, into SMC. 39, 40 Accordingly, donor-derived SMC were detected throughout atherosclerotic vessels in patients who received gendermismatched BM transplants, suggesting the involvement of circulating SMPC in intimal proliferation in humans. 41 Although these studies raised some important concerns, because of non-conformity to the current methodological standards for defining an SMPC phenotype (detailed in Bentzon and Falk 15 ), this hypothesis has received further confirmation after the isolation and phenotypic and functional characterization of SOC from human peripheral and umbilical cord blood. 5, 6 These SMPC after in vitro expansion reproduced several properties of mature SMC; however, the earlier in vivo phenotype of SMPC, prior to in vitro expansion, remains to be established. Later, Metharom et al. 19 reported the isolation of peripheral bloodderived SOC that expressed a chemokine fractalkine receptor CX3CR1 and the monocyte/macrophage markers CD14 and CD68, but not CD11b, CD13, CD33, or CD45. Expanded from single-cell clones, these SOC had noticeably reduced levels of CD14 and CD68 but retained stable levels of CX3CR1, expressed high levels of aSMA, SM-MHC, and calponin, produced SM22a upon stimulation with platelet-derived growth factor-BB (PDGF-BB), and showed remarkably reduced phagocytosis compared with macrophages. In addition, CX3CR1-positive SOC, which were responsive to angiotensin II and to the calcium channel blocker nifedipine, were identified Figure 1 Immunocytochemical characterization of umbilical cord blood-derived EPC and SMPC. Endothelial and smooth muscle colony outgrowth cells were isolated and expanded as described by Le Ricousse-Roussanne et al. 6 Cell cultures were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in Dulbecco's modified phosphate-buffered saline and immunostained using the indicated differentiation marker-specific antibody followed by a fluorescence-conjugated species-specific secondary antibody. Nuclei were stained with DAPI (blue). Scale bar, 50 mm. in mouse BM. 42 In a mouse model of mild carotid artery injury, transplanted BM-derived CX3CR1-positive SOC were shown to home to sites of vascular lesion and differentiate into SMC in a CX3CR1/ fractalkine-dependent manner. 43 Taken together, these results indicate that CX3CR1 may be an earlier marker of SMPC. An additional earlier SMPC marker has been recently suggested by the study of Bobryshev et al. 44 on Musashi-1 expression in human arterial tissue. Musashi-1, an RNA-binding protein and a putative marker of intestinal and neuronal stem cells, was unexpectedly detected within the coronary arterial wall and was found to be significantly up-regulated in atherosclerotic plaques. Using double-staining experiments together with laser-capture microdissection and electron microscopy analysis, the authors demonstrated that Musashi-1-expressing cells either were negative for any known arterial intimal differentiation marker or were positive for aSMA. Taking into account the localization of the cells at the luminal surface of arteries and in areas of neovascularization of atherosclerotic plaques, the authors hypothesized that Musashi-1/aSMA double-positive cells are putative circulating SMPC. The site(s) of origin of circulating SMPC is currently not determined. It is plausible that similar to other circulating progenitors, such as EPC and HPC, SMPC are derived from BM. In agreement with this hypothesis is the recent identification of CX3CR1-positive SOC in mouse BM. 42 However, the mobilization of SMPC into the blood stream from other 'vasculogenic' sites in the body cannot be ruled out. Several progenitor cell types with a phenotype partially overlapping with that of SMPC have been identified in the circulation. Sugiyama et al. 45 demonstrated that sorted CD14/CD105-double-positive mononuclear cells from human peripheral blood differentiate into SMC-like cells (SMLC) after incubation for several days in the presence of fibroblast growth factor-2 and transforming growth factor-b (TGF-b). In contrast to their immature and proinflammatory initial phenotype, differentiated SMLC expressed several SMC markers, including aSMA, calponin, and SM22a, but not SM-MHC, and contracted in response to angiotensin II or phenylephrine. Related BM-derived cell populations, presenting an inflammatory monocytic phenotype and expressing aSMA, but not SM-MHC, were shown to accumulate at sites of vascular injury in mouse models of vascular disease. 46 Because they express CD14, the nature of these SMLC remains unclear. They cannot be referred to as circulating MSC, 45 considering the recently adopted definition of MSC that implies CD14-negativity. 47 Instead, SMLC are in the category of fibrocytes, circulating BM-derived cells bearing features of both fibroblasts and monocytes and usually defined as CD34 and collagen-1 co-expressing cells. 48 
Resident vessel wall SMPC
It is presently well documented that BM and circulating cells are not the only source of vascular progenitors. 49 -51 Hu et al. 52 were the first to identify, in mouse aortic roots, adventitial cells that were positive for progenitor markers stem cell antigen 1 (Sca-1), c-kit, CD34, and Flk1 and negative for the embryonic stem marker SSEA-1. When cultured in the presence of PDGF-BB, these cells gave rise to SMC. After transfer to the adventitial side of vein grafts and transplantation into ApoE-deficient mice, the adventitia-derived Sca-1 + cells engrafted into atherosclerotic lesions of the intima. The phenotype of the aortic adventitial Sca-1 + cells was further refined by Passman et al. 8 These authors showed that Sca-1 + cells resided within a particular compartment of the adventitia located at the interface between the media and adventitia and expressed sonic hedgehog (Shh), which is a morphogen and a growth factor common to many developmental tissues including the vasculature. 
Perivascular progenitors
In addition to the tunica adventitia and media/adventitia interface, resident vascular progenitors were found associated with microvessels in a niche historically ascribed to pericytes, which are contractile cells currently defined as cells embedded within the vascular basement membrane, and surrounding EC. 58 Pericytes express shared markers with SMC and have a common embryonic origin, at least with SMC of the same anatomical region. 31, 59 Moreover, there is no known marker allowing discrimination of pericytes from SMC, as several markers routinely used to define pericytes, including chondroitin sulfate proteoglycan NG2, PDGF receptor-b (PDGFR-b), and regulator of G-protein signalling 5, 60 are also expressed by SMC and by some other cell types. Pericytes were believed to belong to the SMC lineage, although later evidence indicated that they are indistinguishable from MSC. 61, 62 Multiple studies highlighted, however, the vast heterogeneity in the phenotype and ontogeny of pericytes from different vascular beds as well as the difficulty in correctly identifying the diverse cell types within this population. 63 
Endothelial-to-mesenchymal transition
Recent findings revealed an apparent phenotypic plasticity in vascular progenitor cells and the possibility of phenotypic interconversion between EPC and SMPC. A major role in the regulation of this process has been assigned to TGF-b. 65 Depending on the culture period necessary to initiate endothelial differentiation and growth (4-7 vs. 14 days and more), EPC have been previously categorized into two main types, early EPC and late EPC. While early EPC likely belong to the monocyte/macrophage lineage, 66 69 when cultured in the presence of TGF-b1. This transition consisted of a decrease in endothelial marker expression and loss of endothelial-specific functions, up-regulation of SMC-specific markers, cytoskeletal rearrangement, and acquisition of a contractile phenotype. The TGF-b1/TGF-b receptor type II-Alk5/Smad2 axis has been implicated in these events. 21, 22 Furthermore, the modulation of endothelial nitric oxide (NO) synthase activity and the endogenous NO levels seemingly determine whether EPC maintain their phenotype or transdifferentiate into SMPC. 65 Imamura et al. 21 showed that infused green fluorescence protein-labelled EPC engrafted onto neointima could differentiate into SMC in situ and may contribute to the aggravation of intimal hyperplasia, albeit the SMC phenotype was assigned based solely on the aSMA positivity. The true nature of the TGF-b1-induced phenotypic modulation in EPC, however, is not entirely understood. The phenotypic entity of EPC and SMPC is still being debated and highly specific markers for defining these phenotypes unambiguously have not yet been uncovered. The contamination with MSC or with more immature APC of cell isolates used in the studies on EPC-to-SMPC conversion has not been ruled out. Both MSC 70 and APC 71, 72 are capable of differentiating into SMC. MSC, APC, and related very small embryonic-like stem cells were found to be mobilized into peripheral blood in patients with myocardial ischaemia, stroke, and acute cardiovascular failure 73 -75 and, therefore, may be isolated along with putative EPC.
Thus, whether TGF-b1 induces authentic EPC to SMPC transdifferentiation or just favours the expansion and differentiation (into SMC) of MSC and/or APC contaminating the EPC samples expanded in vitro needs to be elucidated.
SMPC in cardiovascular disease
Mural cells of the SMC lineage, which include vascular SMC in the large-and medium-sized arteries and veins, pericytes in capillaries, post-capillary venules, and terminal arterioles, are essential for the maintenance of vessel integrity and homeostasis through the regulation of EC survival, quiescence, proliferation, and branching morphogenesis and through the production of extracellular matrix (ECM) proteins. Genetic studies in mice demonstrated that the impairment of signalling pathways implicated in mural cell recruitment prevents maturation and stabilization of developing vessels and leads to early death because of cardiovascular abnormalities, microvascular haemorrhaging, and oedema formation, thus highlighting the crucial role of SMPC in embryonic vasculature formation. 76 -80 The experimental data regarding the role of SMPC in adult vessels are rather scarce. However, SMPC have recently been recognized as playing a special role in cardiovascular biology, and the size of the circulating SMPC pool was correlated with cardiovascular health.
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Functions of SMPC in atherosclerosis and neointimal hyperplasia
Functional studies on the role of SMPC in intimal proliferation associated with atherosclerosis and other vascular disorders, including transplant graft vasculopathy, balloon-induced injury, and angioplasty restenosis, were mainly focused on SMPC contributions to neoantimal hyperplasia by virtue of plaques invading, proliferating, and producing ECM components. Although earlier reports suggested the predominant role of circulating progenitors, 39, 40, 81 later analyses, using a larger panel of SMC markers and high-resolution microscopy with Z-stack acquisition and three-dimensional reconstitution, essentially demonstrated that local cells from the vessel wall are involved in hyperplasic intimal remodelling, 82 -84 whereas aSMA + cells of BM origin are mostly monocytes/macrophages, accumulating during the initial stages of the inflammatory response, and rarely if ever give rise to SMC. 46, 85 Vasa vasorum, which is a microvascular network emanating from the adventitial layer and supplying oxygen and nutrients to the external layers of the vascular wall, has been implicated in the progression of atherosclerosis. 86 Angiogenesis, consisting of vasa vasorum expansion from the adventitia through the media and invasion of atherosclerotic plaques, has been recognized as an integral part of the atherogenic process in humans and in animal models of the disease 87 and was found to contribute to neointima formation induced by other types of injury to the vessel wall. 88 While an increase in adventitial microvessels has been associated with an enhancement of intimal thickening that was initiated independently of vasa vasorum proliferation, the relationship between intraplaque angiogenesis, plaque stability, and disease outcome is not completely understood. 89 It has been proposed that angiogenesis within coronary atherosclerotic plaques leads to the formation of more immature microvessels liable to rupture and potentially responsible for acute coronary events. 90 Indeed, recent ultrastructural analysis showed that intraplaque atherosclerotic coronary artery microvessels in autopsies from sudden death donors were lined by abnormal EC with membrane blebs, open junctions, and basement membrane detachment, accounting for microvascular leakage and intraplaque haemorrhage. 91 Furthermore, mural cell coverage was incomplete in the microvessels from coronary atherosclerotic plaques; however, no association between incomplete mural cell coverage and intraplaque leakage has been found in this study. In contrast, Dunmore et al. 92 demonstrated that the coverage with SMC in intraplaque microvessels was significantly lower in symptomatic carotid disease patients compared with asymptomatic patients. In both studies, the intraplaque microvessel density was significantly correlated with more advanced stages of atherosclerosis. 91, 92 Several lines of evidence suggest that SMPC may be involved in intraplaque and adventitial angiogenesis. First, the recruitment of circulating or resident SMC marker-positive cells to sites of atherosclerotic lesions and otherwise injured hyperplasic neointima is presently well documented, and some studies show that these putative SMPC were localized in adventitial and intraplaque neomicrovessels in humans. 19, 44 Secondly, incomplete coverage of intraplaque microvessels with mural cells 91, 92 and the correlation of SMC depletion in intraplaque microvessels with more severe disease 92 indicate that impaired SMPC recruitment may contribute to vessel leakage and plaque rupture. Interestingly, significantly reduced levels of peripheral blood smooth muscle colony-forming cells were reported in patients with acute coronary syndrome compared with stable angina patients, suggesting that the additional mechanism underlying plaque instability may involve poor SMPC mobilization from BM. 20 Thirdly, plaque growth, composition, and stability were found to be modified following the infusion of UCB-SMPC 20 or BM-derived SMLC 81, 93 in mouse models of neointimal hyperplasia. However, infused cells were infrequent in plaques and contributed marginally to the cellularity of the lesions, suggesting that these cells influenced plaque progression either through paracrine mechanisms or/and through their impact on the accompanying pathological processes, including inflammation and angiogenesis.
Therapeutic use of SMPC
Atherosclerosis underlies a greater part of cardiovascular incidents, such as acute coronary syndrome, stroke, and critical limb ischaemia, representing the major causes of morbidity and mortality worldwide. Ischaemic disease, resulting from reduced blood supply through obstructed vessels, is frequently aggravated by associated risk factors, including hypertension, diabetes, obesity, and advanced age, which in addition to the impairment of EC and SMC functions reduce mobilization and the reparative potential of endogenous vascular progenitor cells. 20, 94, 95 Until recently, no effective therapies have been developed for patients with advanced disease. 96 In past decades, cell therapy-based approaches using vascular progenitor cells have emerged as promising therapeutic options for patients not eligible for currently practiced surgical or endovascular revascularization procedures. 97 -99 Although the therapeutic potential of EPC in vascular repair and bio-engineering of blood vessels has been evaluated in numerous pre-clinical and clinical studies, the therapeutic potential of SMPC has only recently being explored. During the last decade, it has become increasingly evident that transplantation of EPC alone gives rise to vessels displaying poor performance over time and lacking mechanical strength, whereas mural cell co-engraftment promotes vessel formation by EC, enhances vessel function, and increases vessel longevity. 100, 101 Accordingly, using a mouse model of hindlimb ischaemia, we demonstrated that co-transplantation of umbilical cord blood-derived EPC and UCB-SMPC expanded in vitro significantly enhanced EPC-induced improvement in arteriolar and capillary density and foot perfusion, whereas infusion of UCB-SMPC alone affected marginally any of these parameters. 102 Moreover, a greater engraftment of EPC into vessels within the ischaemic muscle and a more complete coverage with SMC/pericytes were seen in mice co-transplanted with EPC and UCB-SMPC compared with the EPC-only group, whereas UCB-SMPC did not engraft to vessels in any setting. Using an RNA interference approach, we demonstrated that signalling through the UCB-SMPC-secreted angiopoietin-1/ EPC-expressed Tie-2 pair has been implicated in these potentiating effects. 102 Our recent results indicate that co-implantation of SMPC would also enhance the therapeutic benefits of EPC in post-stroke ischaemia. We demonstrated that injection of EPC along with UCB-SMPC in a mouse model of permanent focal ischaemia, induced by middle cerebral artery occlusion, enhances angiogenesis and stimulates the formation of more mature vessels with subsequent improvement of cerebrovascular architecture. 103 These events led to significantly higher neuroblast survival and migration towards the lesion and increased neurogenesis and functional recovery. Taken together, our results suggested that SMPC may enhance the therapeutic potential of EPC in ischaemic disease, through more thoroughly regulated angiogenesis and formation of more stable vessels with improved mechanical and functional properties. There are rather contradictory data on the impacts of SMPC transplantation on existing atherosclerosis. Some studies reported on the aggravation of atherosclerotic lesions and inflammation after transplantation of BM-derived SMLC expanded in vitro. 93, 104 In contrast,
Zoll et al. 20 showed that preventive intravenous infusion of UCB-SMPC into ApoE 2/2 RAG 2/2 mice reduced macrophage invasion and the size of atherosclerotic lesions as well as, in a curative setting, increased SMC and collagen content, which are indicative of a delay in disease progression and a switch in the plaque phenotype towards a more stable one. 20 Although the authors did not analyse in detail the intraplaque localization of SMC in UCB-SMPC-treated mice, it is conceivable that more SMC were recruited to intraplaque microvessels, thus improving vessel stability and preventing plaque rupture. In the same vein, a recent proteomic profiling analysis of SOC from human peripheral blood showed that they produced rather low levels of proteolytic enzymes and inflammatory cytokines and were capable of secreting ECM; consequently, they were less angiogenic in vitro and in vivo. 105 Using these cells for therapeutic purposes would likely help to limit excessive development of immature leaky neovessels and would result in an improvement of reperfusion through normalization of the architecture and function of the vascular bed. An additional source of SMPC for therapeutic revascularization had recently emerged from studies on the in vitro derivation of embryonic stem cells (ESC) and induced pluripotent stem cells (iPC). The conditions for ESC and iPC differentiation into SMC were partially characterized and consist of the following: (i) growth in the presence of soluble growth factors and cytokines, typically PDGF-BB and TGF-b1; (ii) culture on specific matrix protein coatings, frequently collagen IV, or on stromal feeder cells; and (iii) particular physical manipulations, such as the application of shear stress (reviewed in Kane et al. 106 and Cheung et al. 107 ). In general, these procedures give rise to the less mature bi-potent EC/SMC or tri-potent EC/ SMC/cardiomyocyte differentiation intermediates with highly variable phenotypes. Determining which of these intermediates correspond to the endogenous bone fide SMPC and what are the precise culture conditions and time window that favour the generation of SMPC from ESC and iPC demands further investigation.
Conclusions
Several endogenous SMPC populations with varying phenotypes have been identified and characterized in the circulation, BM, and vascular wall. The phenotypic entity of vascular SMPC is not entirely defined and remains an evolving area of research, with some putative earlier SMPC markers suggested in the past years. Recent evidence indicates that SMPC are mobilized following different types of injury to vessels and contribute to angiogenesis and intimal proliferation occurring in cardiovascular disease, although the origin of SMPC at sites of vascular injury is still being debated. Transplantation of SMPC along with EPC supports the formation of more functional and stable vessels persistent over time, providing a powerful tool for regenerative medicine. It is still questionable as to whether transplantation of SMPC will restrain or accelerate the atherogenic process, but this certainly will depend on the source and phenotype of SMPC and their culture conditions. Using SMPC preparations that retain expression of monocyte/ macrophage markers will probably favour inflammation and worsen the disease, whereas transplantation of SOC with a more complete SMC phenotype will likely improve vascular disease through normalization of neovessels and stabilization of atherosclerotic plaques. Further research is needed to better understand SMPC ontogeny and phenotypic features allowing, when used for therapeutic purposes, for better therapeutic benefits and increased security regarding the underlying vascular disease.
